Will a gene therapy that edits multiple genes using CRISPR be approved by the FDA before 2030?

In late 2023 the United States Food and Drug Administration (FDA) approved Casgevy, the first ever CRISPR-based gene therapy. Casgevy is a gene therapy for sickle cell disease, which is a hereditary disease caused by a mutation in a single gene (i.e. it’s monogenic).

To count as a YES, a “gene therapy that edits multiple genes using CRISPR” should modify two or more genes in a patient’s genome by using some version of CRISPR (e.g. Cas9, an alternative protein). The gene therapy must be for humans.

Will the FDA approve a multigenic gene therapy using CRISPR technology before 2030?

Get Ṁ600 play money

More related questions